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Background: Rising rates of multi-drug-resistant, gram-positive cocci (e.g., methicillin-resis-
tant Staphylococcus aureus [MRSA], vancomycin-resistant Enterococcus spp. [VRE]) have cre-
ated treatment challenges for clinicians in both the hospital and community settings. These
organisms have become especially problematic for hospitalized patients with pneumonia,
complicated intra-abdominal infections, and skin and skin-structure infections (SSSIs).
Methods: A review of the recent literature (1990 onwards) was undertaken in order to re-
view the epidemiology, diagnostic issues, and clinical trial data of available and forthcoming
therapies for the treatment of multi-drug resistant, gram-positive isolates, with an emphasis
on selected MRSA infections (i.e., pneumonia, SSSI, diabetic foot infections, blood stream)
and infections caused by VRE.
Results: The rate of healthcare-associated MRSA in 2004 rose to an incidence of 59.5% in
the United States compared with data from 1998–2002, making MRSA the predominant gram-
positive etiology of S. aureus infections in hospitalized patients. Methicillin-resistant S. au-
reus has also emerged as an important pathogen in both the non-ICU and community set-
tings. Similarly, 28.5% of all enterococcal isolates were identified as vancomycin-resistant in
2003 (a 12% increase). However, these rates may be underestimated, as detection methods for
determining susceptibility have proved to be inadequate. Recognition that prior inadequate
antibiotic therapy is common in patients with antibiotic-resistant bacteria, and is associated
with higher mortality rates, emphasizes the importance of selecting appropriate empiric ther-
apy. Currently available therapies for resistant gram-positive infections include quinupristin-
dalfopristin, linezolid, and daptomycin, although each of these agents has limitations (e.g.,
daptomycin is not indicated for MRSA pneumonia due to inadequate lung tissue penetration
and inactivation by surfactant). Three agents with broad-spectrum activity against gram-pos-
itive organisms that are at an advanced stage of testing include two new glycopeptides (ori-
tavancin and dalbavancin), and a first-in-class glycylcycline (tigecycline). These agents have
demonstrated efficacy in the treatment of SSSIs, including those caused by MRSA.
Conclusions: New antimicrobial agents are needed to combat the increasing prevalence of
multi-drug-resistant, gram-positive pathogens such as MRSA. The emergence of resistance to
available therapies such as vancomycin underscores this urgency.
University of Michigan School of Medicine, Ann Arbor, Michigan.
This paper was supported in part by Wyeth Pharmaceuticals.
S-5
S-6 NAPOLITANO
INFECTIONS CAUSED BY multi-drug-resistant,gram-positive cocci [including methicillin-
resistant Staphylococcus aureus (MRSA), methi-
cillin-resistant coagulase-negative Staphylo-
coccus spp. (MR-CoNS), and vancomycin-
resistant Enterococcus spp. (VRE)] continue to
increase in prevalence. At present, gram-pos-
itive pathogens are the leading cause of
healthcare-associated infections (e.g., pneu-
monia and bacteremia) and skin and skin-
structure infections, including surgical site in-
fections. The increasing emergence of MRSA
is of great concern, as MRSA strains are often
multi-drug-resistant [1]. Infections due to
MRSA are an important cause of morbidity
and mortality in hospital patients. Moreover,
increased incidences of outpatient MRSA in-
fections have been reported recently [2]. It is
well established that there is a higher mortal-
ity associated with MRSA infections com-
pared to methicillin-susceptible S. aureus
(MSSA) infections [3]. Resistant gram-positive
pathogens are also emerging as dominant iso-
lates in surgical patients, with MRSA now a
leading cause of surgical site infection and
other perioperative infections [4].
During 1996, 4,065 consecutive S. aureus
strains from unique patients were collected 
in 21 hospital laboratories worldwide. The
strains, their resistance patterns, and hospital
demographic data were forwarded to Sarisa
Study Group, where the strains were typed and
the data were analyzed [5]. Methicillin-resis-
tant S. aureus occurred at low levels in hospi-
tals in Northern Europe (1%), higher levels 
in middle European countries, regions of the
United States, New Zealand, and Australia
(6–22%), and very high levels in Southern Eu-
ropean countries as well as in parts of the
United States, Asia, and South Africa (28–63%).
Methicillin-resistant S. aureus strains found in
large hospitals were more resistant to other an-
tibiotics than MRSA isolates found in smaller
hospitals serviced by the same laboratory. In-
tensive care units (ICUs) had the highest preva-
lence of MRSA. Strains from the lower respira-
tory tract showed the highest prevalence of
resistance, and blood isolates the lowest. A
dominant MRSA clone was found in hospitals
with an MRSA frequency of more than 10%.
Pulsed-field gel electrophoresis typing recog-
nized several of these clones as epidemic in-
ternational strains of MRSA.
Current data from the National Nosocomial
Infections Surveillance (NNIS) report of the
U.S. Centers for Disease Control and Preven-
tion (CDC) document that in ICU patients,
59.5% of all S. aureus isolates are now methi-
cillin-resistant (Fig. 1), making MRSA the pre-
dominant pathogens of S. aureus infections in
critical illness [6]. This represents a 12% in-
crease in the rate of MRSA for 2004 data com-
pared to the five prior years (1999–2003). Fur-
thermore, MRSA has now emerged as an
important pathogen in both the non-ICU and
community settings (Table 1).
There has also been a substantial increase in
VRE prevalence, with 28.5% of all enterococcal
isolates identified as vancomycin-resistant,
representing a 12% increase in the resistance
rate for 2003, compared to the mean resistance
rates of the five prior years. In contrast, rates
of methicillin-resistance for coagulase-negative
staphylococci (MR-CNS) remain stable, but at
a high rate, with 89.1% of all isolates being me-
thicillin-resistant.
DIAGNOSIS
The diagnosis of infections caused by multi-
drug-resistant gram-positive cocci requires 
detection of the gram-positive isolates from
clinical specimens by clinical microbiology lab-
oratories. Current methods require a number
of days for growth of the pathogen in culture,
subsequent isolation of pure colonies, and then
identification and susceptibility testing that
may require several more days to complete and
report. This delay in pathogen characterization
requires the use of empiric antimicrobial ther-
apy for two to three days, and then subsequent
de-escalation of antimicrobial therapy targeted
at the specific pathogens identified. Because
MRSA is a common pathogen in pneumonia,
bacteremia, and SSSI, this strategy leads to an
empiric overuse of antibiotics with MRSA ac-
tivity. The rapid and accurate identification of
MRSA in clinical specimens therefore has im-
portant implications for the therapy and man-
agement of both colonized and infected pa-
tients.
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Rapid detection of MRSA, directly from ster-
ile or non-sterile clinical samples, has recently
been developed and is undergoing testing.
Molecular methods for the rapid identification
of MRSA are generally based on the detection
of a S. aureus-specific gene target and the mecA
gene. However, such methods cannot be ap-
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FIG. 1. Selected antimicrobial-resistant pathogens associated with nosocomial infections in ICU patients. Compari-
son of resistance rates from January through December 2003, with five years prior (1998 through 2002). From [6].
CNS, coagulase-negative staphylococci; 3rd Ceph, resistance to third generation cephalosporins; Quinolone, resistance
to either ciprofloxacin or ofloxacin. *Percent (%) increase in resistance rate of current year (January–December 2003)
compared with mean rate of resistance over previous five years (1998–2002). **Resistance for E. coli or K. pneumoniae
is the rate of nonsusceptibility of these organisms to either third generation cephalosporin group or aztreonam.
TABLE 1. POOLED MEANS AND PERCENTILES OF THE DISTRIBUTION OF ANTIMICROBIAL RESISTANCE RATES BY ALL ICUS
COMBINED, NON-ICU INPATIENT UNITS AND OUTPATIENTS, JANUARY 1998 THROUGH JUNE 2004*
Percentile
Antimicrobial-resistant # # Pooled
Location pathogen units tested mean 10% 25% 50% 75% 90%
All ICUs MRSA 157 22,899 52.90 20.0 32.7 48.1 60.3 67.9
Non-ICU MRSA 56 42,502 46.00 25.6 31.9 44.9 52.0 60.8
Inpatient
Areas
Outpatient MRSA 49 35,489 31.10 15.0 19.3 24.6 30.8 49.7
All ICUs Methicillin-resistant 141 13,553 76.60 57.0 69.4 76.3 83.8 88.4
CoNS
Non-ICU Methicillin-resistant 53 23,525 65.70 52.2 57.1 65.2 71.1 75.9
Inpatient CoNS
Areas
Outpatient Methicillin-resistant 48 16,054 50.20 38.5 43.1 48.9 57.8 61.5
CoNS
All ICUs Vancomycin-resistant 140 14,140 13.90 0 5 13.6 24.3 39.2
Enterococcus spp.
Non-ICU Vancomycin-resistant 55 32,924 12.00 1.9 3.5 7.1 14.2 18.6
Inpatient Enterococcus spp.
Areas
Outpatient Vancomycin-resistant 46 24,840 4.60 0.8 1.3 3.6 6.1 9.3
Enterococcus spp.
CoNS: Coagulase-negative staphylococci; ICU: Intensive care unit; MRSA: Methicillin-resistant staphylococcus
*From [6].
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contaminated specimens, such as nasal sam-
ples without the previous isolation, capture, or
enrichment of MRSA, because these samples
often contain both CoNS and S. aureus, either
of which can carry mecA. One such assay uses
a multiplex quantitative polymerase chain re-
action (PCR), with simultaneous measurement
of the following targets: 1) mecA gene, confer-
ring methicillin resistance, common to both S.
aureus and Staphylococcus epidermidis; 2) femA
gene from S. aureus; and 3) the femA gene from
S. epidermidis. This quantitative approach al-
lows discrimination of the origin of the mea-
sured mecA signal. The assay uses a 96-well
format that allows analysis of 30 swab samples
per run and detection of the presence of MRSA
with exquisite sensitivity compared to optimal
culture-based techniques. The complete proto-
col may provide results in less than six h
(whereas standard procedure requires two to
three days), thus allowing prompt assay results
reporting [7].
Most recently, a real-time multiplex PCR as-
say was described that comprises five primers
specific to the various SCCmec right extremity
sequences, including three new sequences, in
combination with a primer and three molecu-
lar beacon probes specific to the S. aureus chro-
mosomal orfX gene located to the right of the
SCCmec integration site [8]. This real-time PCR
assay has been validated by using a variety of
gram-negative and gram-positive bacterial
species, as well as strains of MSSA, MRSA, 
methicillin-susceptible CoNS (MS-CoNS), and
MR-CoNS from various countries. The assay
was also used to detect MRSA directly from
nasal specimens. The analytical sensitivity of
the PCR assay, as evaluated with MRSA-nega-
tive nasal specimens containing a mixture of
MSSA, MR-CoNS, and MS-CoNS spiked with
MRSA, was approximately 25 colony-forming
units (cfu) per nasal sample.
Also, a qualitative in vitro diagnostic test was
described for the rapid detection of MRSA di-
rectly from clinical specimens, based upon a
real-time PCR and direct detection of MRSA
via amplicon hybridization with a fluorogenic,
target-specific, molecular beacon probe [9].
Samples from 288 patients were analyzed for
the presence of MRSA with this assay, com-
pared to detection by either direct plating or
enrichment broth-selective culture methods.
This assay demonstrated 91.7% sensitivity,
93.5% specificity, 82.5% positive predictive
value, and 97.1% negative predictive value
when compared to culture-based methods. The
specimen processing time from start to result
was approximately 1.5 h.
The real-time PCR assays represent a rapid
and powerful method that can be used for the
detection of MRSA directly from clinical spec-
imens. Assays for rapid identification of VRE
are also under development. A novel suscepti-
bility test based on a chemiluminescence assay
found that PCR is reliable and rapid for detec-
tion of VRE strains in clinical laboratories, and
is associated with a very short incubation time
(2–4 h) [10]. These new assays will require fur-
ther clinical validation.
EMERGING VANCOMYCIN RESISTANCE
Infections caused by drug-resistant patho-
gens are on the increase. With the initial emer-
gence of MRSA, the glycopeptide vancomycin
had been the only uniformly effective treat-
ment for staphylococcal infections. At present,
we have other antimicrobial choices for the
treatment of MRSA infections. This is crucial,
because both glycopeptide resistance gener-
ally and vancomycin resistance specifically
continue to emerge. In 2002, the first two clin-
ical isolates of vancomycin-resistant S. aureus
(VRSA) containing vanA (an enterococcal re-
sistance gene) were recovered in Michigan and
Pennsylvania. Additional studies now suggest
that the first two VRSA isolates were the result
of independent genetic events [11]. Additional
infections due to S. aureus with reduced sus-
ceptibility to glycopeptides (GISA) have been
identified in the United States [12]. The emer-
gence of GISA strains emphasizes the impor-
tance of the appropriate use of antibiotics, the
laboratory capacity to identify resistant strains,
and the importance of infection control prac-
tices [13].
Some S. aureus isolates have glycopeptide
minimal inhibitory concentrations (MICs) in
the susceptible range but have subpopulations
that grow on 4 mg/L vancomycin, confirm-
ing heteroresistance. Clinical laboratory meth-
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ods for determining susceptibility have proved
to be inadequate for detecting heteroresistance.
A recent study documented that, among MRSA
and MSSA clinical isolates, 149 (66.2%) of 225
and 17 (56.6%) of 30 isolates, respectively, grew
on medium containing 2 mg/L vancomycin; 17
(7.5%) of the MRSA and two (6.6%) of the
MSSA isolates grew on plates containing 4
mg/L vancomycin. One isolate grew on a plate
containing 6 mg/L vancomycin. This isolate es-
caped detection by routine susceptibility test-
ing, but had a vancomycin MIC of 6 mg/L.
These observations suggest that GISA-like S.
aureus isolates are circulating undetected, and
that a continuum of decreased susceptibility
exists in unselected isolates [14].
More recently, infections due to S. aureus
with reduced vancomycin susceptibility (SA-
RVS) have been reported increasingly [15]. The
U.S. Centers for Disease Control and Pre-
vention (CDC) S. aureus Epidemiology Study
Group recently reported 19 case patients with
infection due to SA-RVS; four infections were
due to vancomycin-intermediate S. aureus
(VISA; MIC 8 mg/L) and 15 were due to non-
VISA SA-RVS (MIC  4 mg/L). Case patients
both with and without VISA infection had 
similar clinical presentations and outcomes; 
the overall attributable mortality rate was 63%.
Isolates recovered from case patients had het-
erogeneous pulsed-field gel electrophoresis
banding patterns, regardless of the MIC of van-
comycin. This study confirmed that indepen-
dent risk factors for SA-RVS infection included
antecedent vancomycin use and prior oxacillin-
resistant S. aureus infection two or three months
prior to the current infection [16].
COMMUNITY-ACQUIRED 
MRSA (CA-MRSA)
Methicillin-resistant S. aureus has tradition-
ally been considered a healthcare-associated
pathogen in patients with established risk fac-
tors. However, MRSA has emerged in patients
who have never been hospitalized or treated
with vancomycin, known as community-ac-
quired MRSA (CA-MRSA). A prospective co-
hort study of 1,100 MRSA infections compared
community-acquired (131, 12%) to healthcare-
associated (937, 85%) isolates [17]. Skin and soft
tissue infections were more common among
community-associated cases (75%) than among
health-care-associated cases (37%) (odds ratio
[OR] 4.25; 95% confidence interval [CI],
2.97–5.90). Although CA-MRSA isolates were
more likely to be susceptible to four antimi-
crobial classes (adjusted OR, 2.44; 95% CI,
1.35–3.86), most community-associated infec-
tions were treated initially with antimicro-
bials to which the isolate was not susceptible.
Community-associated isolates typically pos-
sess different exotoxin gene profiles (e.g., 
Panton Valentine leukocidin genes) compared
with healthcare-associated isolates. This study
documented that community-associated and
health care-associated MRSA cases differ de-
mographically and clinically, and their respec-
tive isolates are microbiologically distinct. 
This suggests that most community-associated
MRSA strains did not originate in health care
settings, and that their microbiological features
may have contributed to their emergence in the
community. Clinicians should be aware that
therapy with beta-lactam antimicrobials can no
longer be relied on as the sole empiric therapy
for severely ill outpatients whose infections
may be staphylococcal in origin.
The genomes of two disease-causing S. au-
reus strains isolated from distinct clinical set-
tings have been sequenced: A recent hospital-
acquired representative of an epidemic MRSA
clone (MRSA252), and a representative of an 
invasive community-acquired MSSA clone
(MSSA476) [18]. The genome sequences of both
had a well conserved core region, but differed
markedly in their accessory genetic elements.
This study documented the crucial role that ac-
cessory elements play in the rapid evolution of
S. aureus. The differential distribution of large
mobile elements carrying virulence and drug-
resistance determinants may be responsible for
the clinically important phenotypic differences
in these strains, but additional study is re-
quired for confirmation.
Outbreaks of CA-MRSA infections, particu-
larly skin and skin structure infections, have
been described in schools, prison settings, and
organized sports [19]. In many of these cases,
a highly conserved CA-MRSA clone was iden-
tified that carried the gene for Panton-Valen-
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tine leukocidin and the gene complex for
staphylococcal-cassette-chromosome mec type
IVa resistance. Longitudinal studies have
linked this dramatic increase in MRSA infec-
tions to an expanding community reservoir of
MRSA genotypes with intrinsic community
survival advantage [20]. In practice, however,
it is difficult to delineate whether an MRSA iso-
late causing infection is community-acquired
or healthcare-associated. Rapid real-time PCR
assays to detect the Panton-Valentine leuko-
cidin gene in S. aureus have been described, but
are not yet in clinical use [21]. Although this in-
formation is crucial for epidemiologic studies,
there is question as to whether it would be use-
ful to the treating clinician.
Unlike healthcare-associated MRSA, CA-
MRSA isolates are often susceptible to several
non-beta-lactam drugs, including clindamy-
cin, trimethoprim-sulfamethoxazole, and newer
tetracyclines. However, concern over the pos-
sibility of emergence of clindamycin resistance
during therapy has discouraged clinicians from
clindamycin use [22]. Laboratory testing (e.g.,
the erythromycin-clindamycin “D-zone” test)
can separate strains that have the genetic po-
tential for inducible macrolide-lincosamide-
streptogramin B resistance (i.e., the presence of
erm genes) during therapy from strains that are
fully susceptible to clindamycin. A recent sin-
gle-institution study confirmed that 56% of 161
erythromycin-resistant, clindamycin-suscepti-
ble clinical S. aureus isolates manifested induci-
ble clindamycin resistance, with a significantly
higher proportion (78%) seen in pediatric iso-
lates [23]. Despite in vitro susceptibility of CA-
MRSA isolates to these oral antimicrobials, lit-
tle data is available regarding their clinical
efficacy.
MANAGEMENT
Appropriate antimicrobial therapy is crucial
for the successful treatment of infections due to
antibiotic-resistant gram-positive pathogens. It
has been documented that inadequate antibi-
otic therapy is common in patients with an-
tibiotic-resistant bacteria such as MRSA, and is
associated with higher mortality rates [24,25].
It is therefore of utmost importance to choose
the correct empiric treatment for patients at risk
for MRSA infection, as well as for patients who
have documented MRSA infections.
Antimicrobial agents that are available cur-
rently for the treatment of MRSA infections 
include vancomycin, the streptogramin com-
bination quinupristin-dalfopristin, the oxazo-
lidinone linezolid, and the cyclic lipopeptide
daptomycin (Table 2). All of these drugs are ac-
tive against gram-positive bacteria, including
most multi-drug-resistant strains. Linezolid
has demonstrated superiority to vancomycin in
clinical and microbiologic cure rates in the
treatment of MRSA complicated skin and soft-
tissue infections, and possibly pneumonia.
Linezolid is available in intravenous (IV) and
an oral form with 100% bioavailability, offer-
ing clinicians the option to use oral therapy at
the initiation of treatment, or to switch to oral
therapy from initial IV therapy. The use of the
oral formulation of linezolid can reduce hospi-
tal length of stay significantly [26].
Daptomycin exerts rapid bactericidal activ-
ity in vitro, but is approved currently by the
U.S. Food and Drug Administration (FDA) for
the treatment of skin and soft-tissue infections
only. Cyclic lipopeptides such as daptomycin
have a unique mechanism of action by disrup-
tion of bacterial transmembrane electric poten-
tials, with less likelihood for development of
cross-resistance. Spontaneous acquisition of re-
sistance in vitro is rare; hopefully this charac-
teristic will extrapolate to the clinical setting.
Rapid bactericidal activity, low potential for re-
sistance, and a reassuring safety profile make
daptomycin a useful addition to the armamen-
tarium of antibiotics active against gram-posi-
tive pathogens [27].
Three drugs with broad-spectrum activity
against gram-positive organisms are in Phase
3 clinical trials: Two new glycopeptides with
potent bactericidal activity and long half-lives
(oritavancin and dalbavancin), and tigecycline
[28], a new, semisynthetic glycylcycline. These
drugs have all shown efficacy in the treatment
of SSSI. Tigecycline is a novel, first-in-class 
glycylcycline with expanded broad-spectrum
activity against gram-positive, gram-negative,
aerobic, anaerobic, and atypical bacterial
species, including many resistant pathogens
(i.e., VRE, MRSA, and penicillin-resistant Strep-
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tococcus pneumoniae). This new antibiotic is
unique in that it demonstrates broad gram-pos-
itive and gram-negative activity. The in vitro ac-
tivity of tigecycline and comparator agents was
determined for 3,498 recent (2000-2003) isolates
of S. aureus recovered from patients with either
nosocomial or community-acquired infections
[29]. Oxacillin-susceptible and -resistant S. au-
reus from both patient populations displayed
identical results for tigecycline (MIC50 and
MIC90 of 0.25 mg/L and 0.5 mg/L, respec-
tively) and all strains were inhibited by 1 mg/L
or less. Whereas cross resistance to other an-
timicrobial classes was present in oxacillin-re-
sistant strains, susceptibility to tigecycline re-
mained unaffected, making the compound an
attractive candidate for treatment of both hos-
pital- and community-acquired serious staphy-
lococcal infections.
The in vitro activities of tigecycline and com-
parators were tested against 11,859 recent (2000
and 2002) bacterial strains recovered from pa-
tients in 29 countries with community-acquired
respiratory tract disease (3,317 gram-positive
and -negative strains) and skin and soft-tissue
infections (8,542 gram-positive strains) [30]. All
oxacillin-susceptible and -resistant S. aureus
(5,077 strains; tigecycline MIC90, 0.5 mg/L) 
and coagulase-negative staphylococci (1,432
strains; MIC90, 0.5 mg/L), penicillin-suscepti-
ble and -resistant S. pneumoniae (1,585 strains;
MIC90,  0.25 mg/L), viridans group strepto-
cocci (212 strains; MIC90,  0.25-0.5 mg/L), van-
comycin-susceptible and -resistant enterococci
(1,416 strains; MIC90, 0.25–0.5 mg/L), beta-
hemolytic streptococci (405 strains; MIC90,
 0.25 mg/L), beta-lactamase positive and 
negative Haemophilus influenzae (1,220 strains;
MIC90, 1 mg/L), Moraxella catarrhalis (495
strains; MIC90, 0.25 mg/L), and Neisseria menin-
gitidis (17 strains; MIC90,  0.12 mg/L) were 
inhibited by 2 mg/L or less of tigecycline.
Whereas potency of tetracycline and doxycy-
cline markedly decreased in various resistant or-
ganism subsets, tigecycline was unaffected, with
an overall MIC90 of 0.5 mg/L. These findings
confirm that tigecycline maintains a truly broad
spectrum of activity while enhancing potency.
TABLE 2. COMPARISON OF MRSA ANTIMICROBIALS
Vancomycin Quinupristin/Dalfopristin Linezolid Daptomycin




Route IV IV (central) IV or PO IV
Dosing Variable, Q 8–12 h, altered based on Q 12 h Q D
depending on hepatic function
renal function







Disadvantage Difficulty in Infusion-related Drug Drug
dosing, thrombophlebitis and acquisition acquisition
toxicity, inflammation, myalgias, cost cost, not
resistance arthralgias, no activity effective for
(VRE, GISA, against Enterococcus pneumonia
GRSA) faecalis
CSSSI: complicated skin and skin structure infections; GISA: glycopeptide-intermediate S. aureus; GRSA: glycopep-
tide-resistant S. aureus; IV: Intravenous; MRSA: Methicillin-resistant S. aureus; PO: Oral; QD: Daily; Qxh: Every x hours;
VRE: Vancomycin-resistant enterococcus
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Tigecycline also incorporates stability to com-
mon tetracycline resistance mechanisms, mak-
ing it an attractive candidate for continued clin-
ical development against resistant pathogens.
The safety and tolerability of tigecycline ad-
ministered as single or multiple doses, or at
various infusion rates, were explored in three
Phase 1, randomized, double-blind, placebo-
controlled studies in healthy subjects [31]. Sub-
jects in the ascending multiple-dose study re-
ceived 25-to-100 mg doses of tigecycline as a 1
h infusion every 12 h. The variable volume and
infusion rate study consisted of administration
of a 100 mg loading dose of tigecycline, fol-
lowed by 50 mg every 12 h for five days. Serum
samples were analyzed for tigecycline by vali-
dated methods, either high-pressure liquid
chromatography or liquid chromatography/
tandem mass spectrometry. Systemic clearance
ranged from 0.2 to 0.3 L/h/kg, and the tigecy-
cline half-life ranged from 37–67 h. Tigecycline
had a large volume of distribution (7 to 10
L/kg), indicating extensive distribution into
tissues. Tigecycline exhibited linear pharmaco-
kinetics and was safe and well tolerated in the
dose ranges examined in this study.
The promising data that have emerged re-
cently indicate that six drugs to treat resistant
S. aureus infections may be available within the
next few years. As clinicians, it must be our
goal to determine the appropriate indications
and cost-effectiveness of each of these drugs in
our treatment strategies against S. aureus and
other gram-positive pathogens. Data regarding
clinical efficacy with the use of these antibiotics
in the treatment of specific disease states, in-
cluding pneumonia, SSSI, and bacteremia will
be reviewed to assist in this decision making.
PNEUMONIA CAUSED BY
METHICILLIN-RESISTANT S. AUREUS
Over the past 15 years, the incidence of hos-
pital-acquired pneumonia due to gram-posi-
tive organisms has increased relative to gram-
negative organisms [32]. Staphylococcus aureus
and Pseudomonas aeruginosa are the two most
common causative pathogens in the ICU, and
ventilator-associated pneumonia is the most
common nosocomial infection in the ICU. The
most recent CDC report of the NNIS group
documented that 59.5% of all S. aureus isolates
are methicillin-resistant currently, making
MRSA the most common gram-positive isolate
in healthcare- and ventilator-associated pneu-
monia. Mortality rates for MRSA pneumonia
are high, ranging from 35 to 50%. In a prospec-
tive analysis of all ventilator-associated pneu-
monia caused by S. aureus for a 30-month pe-
riod, Rello et al. documented that mortality
related directly to pneumonia was significantly
higher among patients with MRSA infection
(RR 20.72; 95% CI 2.78–154.35), and previous
antibiotic therapy was the most important risk
factor for developing infection with MRSA [33].
Current options for antimicrobial treatment
of MRSA pneumonia include vancomycin and
linezolid. Quinupristin-dalfopristin is not ap-
proved by the U.S. FDA for the treatment of
pneumonia because the response rate to quin-
upristin-dalfopristin was lower than that to
vancomycin in the treatment of documented
MRSA hospital-acquired pneumonia (clinical
cure rates 30.9% for quinupristin-dalfopristin
vs. 44.4% for vancomycin) in a prospective ran-
domized study [34], although the results are a
subset analysis of a larger trial.
The first multi-national, randomized, double-
blind, controlled trial comparing linezolid and
vancomycin in the treatment of nosocomial
pneumonia documented equivalent clinical
cure (66.4% vs. 68.1%) and microbiologic suc-
cess (67.9% vs. 71.8%) rates [35]. A recent ret-
rospective analysis of data from the two
prospective, randomized, double-blind regis-
tration trials of patients with gram-positive,
nosocomial pneumonia documented that ini-
tial therapy with linezolid was associated with
better survival and clinical cure rates than van-
comycin in the MRSA cohort [36]. This study
utilized a logistic regression analysis to de-
termine the effect of treatment and other base-
line variables on outcome. Logistic regression
analysis confirmed that the survival difference
favoring linezolid remained significant after
adjusting for baseline variables (OR 2.2, 95% CI
1.0–4.8, p  0.05). Furthermore, Kaplan-Meier
survival rates for linezolid vs. vancomycin
were 80.0% vs. 63.5% for the MRSA subset 
(p  0.03) of patients with nosocomial pneu-
monia. There are major limitations to this study
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in that it was a post-hoc subgroup analysis, the
dosing of vancomycin (1g IV q 12 h) in the con-
trol group may have been inadequate, and re-
cent data have documented that clinical failure
rates are higher in patients with MRSA isolates
for which vancomycin MICs are in the 1–2
g/mL range. Finally, the use of quantitative
sputum cultures was not required for the di-
agnosis of pneumonia, but more than 50% of
patients in the S. aureus and MRSA subgroups
had diagnoses made by invasive methods or
blood culture. A further post-hoc analysis in
patients with ventilator-associated pneumonia
(VAP, n  544) documented that linezolid was
an independent predictor of clinical cure (OR
1.8 for all patients, 2.4 for gram-positive VAP,
20.0 for MRSA VAP) and survival (OR 1.6 for
all patients, 2.6 for gram-positive VAP, 4.6 for
MRSA VAP) [37]. Based on these re-analyzed
data, some have recommended the use of line-
zolid as first-line treatment for patients with
MRSA pneumonia. A prospective, randomized
trial projected to enroll 1,200 patients with
healthcare-associated pneumonia is underway
to attempt to validate the findings of the post-
hoc analysis of the first two trials.
Putative improved outcome with linezolid
may be related to the superior intrapulmonary
pharmacokinetics of linezolid compared with
vancomycin. A study of healthy volunteers
who received oral linezolid (600 mg every 12 h
for five doses) documented that linezolid con-
centrations (mean  SD) in the fluid lining the
epithelial surface of the lower respiratory tract
(epithelial lining fluid [ELF]), recovered by
bronchoalveolar lavage, were significantly
higher than plasma concentrations at the 4-h
time point (ELF 64.3  33.1 vs. plasma 7.3  4.9
mcg/mL) and also at the 12-h time point (ELF
24.3  13.3 vs. plasma 7.6  1.7 mcg/mL) [38].
For an MIC of 4, the 12-h plasma area under
the curve (AUC):MIC and maximum concen-
tration:MIC were 34.6 and 3.9, respectively, and
the percentage of time the linezolid concen-
tration remained above the MIC for the 12-h
dosing interval was 100%; the corresponding
ratios in ELF were 120 and 16.1, respectively,
and the percentage of time the linezolid con-
centration remained above the MIC was also
100%. The long plasma and intrapulmonary
half-lives of linezolid and the high drug con-
centrations observed provide a pharmacoki-
netic rationale for the use of linezolid in the
treatment of pulmonary infections.
Similar findings were documented in a study
of 10 adult patients who underwent diagnostic
bronchoscopy and who were administered oral
linezolid (600 mg q 12 h for 6 doses) [39]. Mean
concentrations of linezolid were 13.4 mg/L in
serum and 25.1 mg/L in ELF, achieving a mean
site:serum concentration of 8.35 for ELF. It is
known that vancomycin penetration into ELF
is significantly lower than plasma. A study of
14 critically ill, ventilated patients who re-
ceived vancomycin for at least five days docu-
mented that ELF vancomycin concentrations
ranged from 0.4 to 8.1 mcg/mL (mean, 4.5
mcg/mL), versus a simultaneous mean plasma
concentration of 24 mcg/mL (range, 9-37
mcg/mL) [40]. There was a significant rela-
tionship (r  0.64, p  0.02) between van-
comycin concentrations in plasma and ELF,
documenting that the blood:ELF drug penetra-
tion was 6:1 (Fig. 2). Using the albumin con-
centration in ELF as a marker of lung inflam-
mation, it was identified that vancomycin
penetration was higher in patients with ELF 
albumin concentrations of 3.4 mg/mL than 
in patients with lower albumin concentrations
( 3.4 mg/mL, p  0.02). These results suggest
that vancomycin distribution into lower respi-
ratory tract ELF is dependent upon the con-
centration in blood, but the ELF concentrations
were well below the minimum inhibitory con-
centrations (MIC) for staphylococci and ente-
rococci in patients with plasma vancomycin
concentrations  20 g/mL, levels that are not
commonly achieved in clinical practice. 
Vancomycin penetration in ELF was also
studied in ten mechanically ventilated patients
with MRSA pneumonia 24 h after the onset of
treatment [41]. Vancomycin was given intra-
venously at a dose of 30 mg/kg/day. Van-
comycin concentrations were detectable in only
four of the 10 patients (range, 1–2.77 mcg/mL),
which is below the MIC for most gram-positive
organisms. Concordance between high plasma
concentrations (20 mcg/mL) of vancomycin
and detectable vancomycin concentrations in
ELF was again noted.
Linezolid also has an advantage over van-
comycin in that no requirement for dosage ad-
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justment is necessary for patients with renal or
hepatic dysfunction. Dosing of vancomycin is
problematic, especially in critically ill patients
with renal dysfunction or changing renal func-
tion in, and often results in under-dosing. Line-
zolid is associated with reversible thrombocy-
topenia; complete blood counts should be
obtained weekly after the first week of therapy.
However, the post-hoc analysis of the two ran-
domized, double-blind studies of patients with
gram-positive nosocomial pneumonia showed
no difference in the incidence of new-onset
thrombocytopenia (linezolid 6.4%, vancomycin
7.7%) [42].
Although daptomycin is approved for the
treatment of SSSI and has rapid bactericidal ac-
tivity against MRSA, it should not be used for
the treatment of pneumonia. Daptomycin does
not achieve adequate intrapulmonary tissue con-
centrations, and there is evidence that the drug
is inactivated by pulmonary surfactant [42a].




MRSA, are an increasingly common cause of
complicated SSSI (cSSSI), including surgical
site infections [43]. It is particularly important
to recognize that MRSA has become the lead-
ing pathogen of surgical site infection in car-
diovascular surgery and orthopedic surgical
patients in many institutions. Current options
for the treatment of cSSSI caused by MRSA in-
clude vancomycin, quinupristin-dalfopristin,
linezolid, and daptomycin [44]. The character-
istics, dosing, advantages and disadvantages of
each of these agents for the treatment of cSSSIs
are seen in Table 2.
Two randomized, open-label clinical trials in
cSSSI (n  893) confirmed similar clinical suc-
cess rates (cure plus improvement) for quin-
upristin-dalfopristin, vs. oxacillin or cefazolin
as comparators (68.2% quinupristin-dalfo-
pristin, 70.7% comparator; 95% CI, 10.1, 5.1
for non-inferiority) [45]. Staphylococcus aureus
was the most frequently isolated pathogen in
both treatment groups, but only 15 patients
with documented MRSA were included in this
trial. A higher rate of drug-related adverse
events (AEs) related to the infusion site was re-
ported for quinupristin-dalfopristin (66.2%)
than for the comparator regimens (28.4%), in-
cluding infusion-site inflammation, pain, and
edema; other infusion-site reactions; and



































FIG. 2. Vancomycin concentrations in the plasma and epithelial lining fluid (ELF) of the lower respiratory tract. The
mean vancomycin concentration in ELF (4.5  2.3 mcg/mL) represented 18% of the simultaneous concentration in
plasma (24  10 mcg/mL). All patients had been receiving vancomycin for at least five days (mean duration of treat-
ment before BAL, 6.6 	 1.75 days; range, five to 11 days). Concentrations in ELF exceeded minimal inhibitory con-
centrations (MICs) for most gram-positive cocci when concentrations in blood were greater than 20 mcg/mL. , pa-
tients with albumin level in ELF of  3.4 mg/mL; , patients with albumin levels in ELF of  3.4 mg/mL. From:
Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar
lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281–286.
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curred in 2.5% to 4.6% of patients, and were the
most frequently reported systemic AEs.
A preliminary study comparing linezolid
and vancomycin documented equivalent clini-
cal and microbiologic cure rates in patients
with cSSSIs caused by MRSA, but had a small
sample size (n  64) [46]. An adequately pow-
ered open-label, multicenter, multi-national
trial of 1,200 hospitalized patients with cSSSIs
randomized patients to receive linezolid (IV or
oral, 600 mg q 12 h) or vancomycin (1 g IV q
12 h) [47]. Clinical cure rates were equivalent
in the intent-to-treat cohort (92% vs. 89%),
which included patients with cellulitis, major
skin abscess, and infected surgical incisions.
Linezolid was superior to vancomycin in the
treatment of MRSA cSSSIs, with clinical cure
rates of 94% vs. 84% (p  0.011) and microbio-
logic efficacy rates of 89% vs. 67% (p  .0001).
Linezolid was also associated with a significant
reduction in IV drug administration (1.8 vs.
12.6 days, p  0.0001) and decreased hospital
mean length of stay (8.1 vs. 10.7 days, p  0.01);
52% (n  308) of the linezolid–treated patients
received only oral linezolid therapy. Post-hoc
analysis of the cohort with surgical site infec-
tion (n  135) documented that clinical success
at test-of-cure was similar in patients treated
with linezolid or vancomycin [48]. However, in
those patients with MRSA isolated, linezolid
yielded a significantly higher microbiologic
cure rate (87% vs. 48%, respectively; 95% CI
16.51-60.27; p  0.01) compared to those who
received vancomycin.
A recent study examined the pharmacoki-
netics and antibacterial activity of oral linezolid
against selective skin/soft-tissue pathogens in
obese patients (50% over their calculated ideal
body weight) [49]. Serum concentrations of oral
linezolid in the obese patients were diminished
compared with those of healthy volunteers, but
still provided prolonged serum inhibitory ac-
tivity against common pathogens associated
with cSSSIs. Bactericidal activity was also ob-
served against selective pathogens. Caution is
advised if treating an obese patient with oral
linezolid for infection with a less susceptible
strain (MIC  4.0 mg/L) of S. aureus.
Daptomycin is approved by the U.S. FDA 
for the treatment of cSSSI, and has excellent
bactericidal activity in vitro against MRSA [50]
and other gram-positive pathogens, including 
MR-CoNS, vancomycin-resistant S. aureus,
penicillin-resistant S. pneumoniae, and VRE [51].
As a parenteral agent that is administered once
daily, it offers a convenient regimen for ther-
apy that is continued after discharge, with a fa-
vorable side effect profile. The safety and effi-
cacy of daptomycin for treatment of cSSSI are
comparable to conventional therapy. In two
randomized, investigator-blinded, multicenter
international trials in 1,092 patients with 
cSSSIs, daptomycin 4 mg/kg/day IV was as ef-
fective as standard therapy (either a semi-syn-
thetic penicillin 4-12 g/day IV or vancomycin
1 g IV q 12 h) [52]. Among 902 clinically evalu-
able patients, clinical success rates were 83.4%
and 84.2% for the daptomycin- and compara-
tor-treated groups, respectively (95% CI for
non-inferiority, 4.0 to 5.6). In patients with
cSSSIs, the AE profiles of daptomycin and van-
comycin were similar. Creatine phosphokinase
(CPK) concentrations increased in 2.8% of dap-
tomycin recipients and 1.8% of patients who re-
ceived standard therapy; only one daptomycin
recipient experienced increased CPK concen-
trations and muscle symptoms that were at-
tributed to therapy.
Several investigational agents, such as dal-
bavancin, oritavancin, and tigecycline, are in
Phase 3 clinical trials and are likely to become
available for clinical use in the near future.
With their long half-lives, these newer antimi-
crobial agents have an advantage of less fre-
quent dosing, and possibly a lower likelihood
for development of resistance [53]. They have
proven activity against highly-resistant organ-
isms, and when available, should ideally be
used only when resistant pathogens are docu-
mented or suspected.
Dalbavancin, a novel glycopeptide with a
long elimination half-life (9–12 days), was
compared to standard antimicrobial therapy
for cSSSIs in a randomized, controlled, open-
label, phase 2, proof-of-concept trial. Adults re-
ceived either 1.1 g of dalbavancin as a single IV
infusion, 1.0 g of dalbavancin IV and then 0.5
g IV one week later, or a prospectively defined
standard-of-care regimen [54]. A gram-positive
pathogen was isolated from samples obtained
from 41 (66%) of 62 patients at baseline; S. au-
reus was the most prevalent species (83% of
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pathogens). Clinical success rates were 94.1%
among patients treated with two doses of dal-
bavancin, 61.5% among patients treated with
one dose of dalbavancin, and 76.2% among 
patients treated with a standard regimen.
Drug-related AEs were similar among the three
groups. These findings suggest that a regimen
of two doses of dalbavancin administered one
week apart is effective in the treatment of com-
plicated, gram-positive, bacterial CSSSIs, and
warrants further study.
Dalbavancin was recently tested in vitro
against 146 staphylococci, and found to be
more potent than other drugs tested, with a
MIC90 of 0.06 mg/L by microdilution. For all
strains, MICs of vancomycin, linezolid, ranbe-
zolid, oritavancin, daptomycin, and quin-
upristin-dalfopristin were all 4.0 mg/L. Dal-
bavancin was bactericidal at four times the MIC
against all six strains tested [55].
Oritavancin, a semisynthetic glycopeptide
with bactericidal activity in vitro against gram-
positive pathogens, is also undergoing investi-
gation for the treatment of patients with cSS-
SIs. In a phase 3, double-blind, randomized
trial, 1,267 patients with cSSSI caused by gram-
positive pathogens were randomized 2:1 to re-
ceive oritavancin (200 mg/day IV for three to
seven days, followed by oral placebo) or van-
comycin plus cephalexin (15 mg/kg van-
comycin q 12 h IV for three to seven days, fol-
lowed by 1 g oral cephalexin twice daily) (total
therapy 10–14 days). Of the 187 patients with
diabetes mellitus in the clinically evaluable pa-
tient population, 62% and 57% of the orita-
vancin and vancomycin patients were cured,
respectively [56]. Efficacy in the oritavancin pa-
tients was achieved with approximately one-
half the number of days of active antimicrobial
therapy. Furthermore, fewer oritavancin pa-
tients (55%) experienced AEs compared to the
vancomycin patients (69%).
Tigecycline, a broad-spectrum glycylcycline
antibiotic, is also being investigated for the
treatment of serious infections in hospitalized
patients, including cSSSIs. Two phase 3, ran-
domized, double-blind studies were conducted
in hospitalized patients with cSSSIs to deter-
mine tigecycline safety and efficacy compared
with vancomycin plus aztreonam (V+A). One
study was conducted in the Americas whereas
the second study was conducted worldwide.
Patient numbers were similar in both studies,
with 537 and 520 patients, respectively, in the
clinically modified, intent to-treat (c-mITT)
population; 397 and 436 patients, respectively,
in the clinically evaluable (CE) population; and
228 and 312 patients, respectively, in the
microbiologically evaluable (ME) population.
Clinical cure rates in the c-mITT and CE pop-
ulations at test-of-cure were similar in both
studies: for the U.S. study (tygecycline vs.
V&A c-mITT 76% vs. 83%; CE 84% vs. 90%);
for the worldwide study (tygecycline vs. V&A
c-mITT 77% vs. 82%; CE 87% vs. 94%. In both
studies, the overall frequency of adverse
events (AEs) was similar between groups. Pa-
tients treated with tigecycline had more nau-
sea and vomiting; however, rash and increases
in alanine transaminase (ALT) and aspartate
transaminase (AST) concentrations were more
frequent in the V 	 A group, resulting in more
frequent discontinuation of therapy [57].
FOOT INFECTIONS OF PATIENTS 
WITH DIABETES MELLITUS 
(DIABETIC FOOT INFECTIONS)
The causative pathogens in diabetic foot in-
fections are gram-positive cocci, with an in-
creasing percentage of multi-drug-resistant
pathogens, including MRSA. A recent large
study of 371 patients with diabetic foot infec-
tion documented equivalent efficacy of line-
zolid and ampicillin/sulbactam for clinical cure
in the intent-to-treat cohort, but linezolid clini-
cal outcomes were superior for patients with in-
fected ulcers (81% vs. 68%, p  0.05) [58].
An analysis of a subset of diabetic patients
with infected ulcers enrolled in two random-
ized, controlled, investigator-blind trials of pa-
tients with cSSSIs (caused presumptively by
gram-positive organisms) compared dapto-
mycin against semi-synthetic penicillins or
vancomycin [59]. Among 133 patients with a
diabetic ulcer infection, 103 were clinically
evaluable; 47 received daptomycin and 56 re-
ceived a comparator. Most infections were mo-
nomicrobial, and S. aureus was the predomi-
nant pathogen. Success rates for patients
treated with daptomycin or the comparators
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were not different for clinical (66% vs. 70%, 95%
CI for non-inferiority, 14.4, 21.8) or microbi-




Blood stream infection (bacteremia) is a com-
mon cause of nosocomial infection in adult
ICUs, comprising 19% of all such infections.
Gram-positive organisms are causative in 64%
of nosocomial bacteremias; the three most com-
mon organisms are CoNS, S. aureus, and ente-
rococci [60]. Data from the NNIS group docu-
mented that 59.5% of all S. aureus isolates in the
U.S. are MRSA. Two recent meta-analyses have
documented that MRSA bacteremia is associ-
ated with a significantly higher mortality rate
than MSSA bacteremia [61,62]. Delayed effec-
tive antimicrobial therapy for S. aureus bac-
teremia was associated with increased infec-
tion-related mortality by multivariate analysis
(OR, 3.8; 95% CI, 1.3-11.0; p  0.01), and was
associated with a longer hospital stay (20.2
days vs. 14.3 days; p  0.05). Furthermore, de-
layed treatment of MRSA bacteremia was as-
sociated with an even higher risk of death (OR,
8.3; 95% CI, 2.6-16.8) [63]. Prompt initiation of
appropriate antibiotic therapy is therefore
mandatory in the treatment of MRSA bac-
teremia. Current options for the treatment of
MRSA bacteremia include vancomycin and
linezolid. There are no prospective randomized
comparative studies of these agents in the treat-
ment of MRSA bacteremia.
There is also concern that heavy vancomycin
use has led to the increased incidence of S. au-
reus isolates with reduced susceptibility to van-
comycin [64]. A recent study [65] assessed all
53 episodes of MRSA bacteremia at a single
hospital during a 12-month period, and com-
pared those due to heterogeneous vancomycin-
intermediate S. aureus (hVISA; n  5, 9.4%)
with those due to vancomycin-susceptible
MRSA (n  48). Patients with hVISA bac-
teremia were more likely to have infections
with a high bacterial load (p  0.001), van-
comycin treatment failure (persistent fever and
bacteremia for 7 days after the start of ther-
apy; p  0.001), and initially low serum van-
comycin concentrations (p  0.006). These clin-
ical markers of hVISA bacteremia may help fo-
cus diagnostic efforts and treatment.
Recent evidence also suggests that van-
comycin’s clinical efficacy is linked with the mi-
crobiological properties of the MRSA clinical
isolates, specifically the vancomycin MIC [66].
Vancomycin susceptibility testing was per-
formed, and bactericidal activity was deter-
mined for isolates from 30 different patients
with MRSA bacteremia for whom clinical and
microbiological outcome data were available.
The majority of these patients had been en-
rolled previously in multicenter prospective
studies of MRSA bacteremia refractory to con-
ventional vancomycin therapy. For MRSA iso-
lates with vancomycin MICs  0.5 mcg/mL,
vancomycin was 55.6% successful in the treat-
ment of bacteremia, whereas vancomycin was
only 9.5% effective in cases in which van-
comycin MICs for MRSA were 1–2 mcg/mL.
Therefore, a substantial risk for vancomycin
treatment failure in MRSA bacteremia begins
to emerge even when increasing vancomycin
MICs are still well within the susceptible range.
This study also demonstrated that vancomycin-
susceptible clinical MRSA isolates may mani-
fest considerable heterogeneity in vitro with re-
spect to vancomycin MIC and the effectiveness
of bacterial killing by vancomycin. These dif-
ferences appear to affect the clinical efficacy of
vancomycin and the probability of successful
treatment of MRSA bacteremia.
New antimicrobial agents for the treatment
of MRSA bacteremia are therefore necessary. A
prospective, randomized trial of linezolid vs.
vancomycin for the treatment of CR-BSI is cur-
rently underway. Daptomycin is also currently
undergoing clinical investigation for the treat-
ment of gram-positive bacteremia. Recently, a
phase 2, open-label, randomized, controlled,
multicenter study of 75 adult patients with
catheter-related blood stream infections (CR-
BSIs) compared treatment with IV dalbavancin,
administered as a single 1000-mg dose, fol-
lowed by a 500-mg dose one week later, with
IV vancomycin administered twice daily for 14
days [67]. Gram-positive bacteria isolated in
this study included coagulase-negative staphy-
lococci and S. aureus, including MRSA. Infected
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patients who received weekly dalbavancin
(n  33) had an overall success rate (87.0%; 95%
CI, 73.2%–100.0%) that was significantly higher
than that of those who received vancomycin
(n  34) (50.0%; 95% CI, 31.5%-68.5%). Adverse
events and laboratory abnormalities were com-




are increasing in incidence in solid organ trans-
plant recipients and have a high associated
mortality rate (up to 83%). Treatment options
for VRE infections include quinupristin/
dalfopristin and linezolid on the basis of in vitro
susceptibility and clinical efficacy from multi-
center clinical trials [68]. Quinupristin/dalfo-
pristin has bacteriostatic activity against van-
comycin-resistant E. faecium (MIC90  2 mg/L)
but is not active against Enterococcus faecalis
(MIC90  16 mg/L). In a non-comparative, open-
label, emergency-use program in 396 patients
who were infected with gram-positive isolates
resistant or refractory to conventional therapy,
or who were intolerant of conventional ther-
apy, quinupristin/dalfopristin was adminis-
tered at 7.5 mg/kg every 8 h [69]. The clinical
response rate in the microbiologically-evalu-
able subset was 70.5%, and a 65.8% overall re-
sponse (favorable clinical and bacteriological
outcome) was observed. Resistance to quin-
upristin/dalfopristin on therapy was observed
in 6/338 (1.8%) of VRE strains. The most com-
mon systemic adverse events related to treat-
ment were arthralgias (9.1%) and myalgias
(6.6%).
Linezolid has bacteriostatic activity against
both vancomycin-resistant E. faecium (MIC90 
2 to 4 mg/L) and E. faecalis (MIC90  2 to 4
mg/L) [68]. This agent was studied in a simi-
lar emergency-use protocol for multi-resistant,
gram-positive infections, with 55 of 133 evalu-
able patients infected with VRE [68]. Cure rates
for the most common sites were complicated
skin and soft tissue, 87.5%; primary bacteria,
90.9%; peritonitis, 91.7%; other abdominal/
pelvic infections, 91.7%; and CR-BSI, 100%. In
a separate blinded, randomized, multicenter
trial for VRE infection at a variety of sites, low-
dose linezolid (200 mg IV every 12 h) was com-
pared to high-dose therapy (600 mg IV every
12 h) with optional conversion to oral admin-
istration [68]. A non-significant dose response
was seen, with a 67% (39/58) and 52% (24/46)
cure rate in the high- and low-dose groups, re-
spectively.
A recent report documented experience with
linezolid in an open-label, compassionate-use
trial at 53 U.S. centers for the treatment of doc-
umented VRE infections in 85 patients with
solid organ transplants [70]. Blood cultures
were positive for VRE in 43 patients, whereas
42 patients had other sites of infection. Fifty-
three percent of patients responded well to
treatment, with clinical resolution of the infec-
tion (62.4% survival rate). The mean duration
of therapy for cured patients was 23.5 days.
Thirty-two patients died (37.6% mortality rate),
28 due to sepsis and organ failure (32.9% fail-
ure rate), and four due to unrelated causes. Ad-
verse reactions to linezolid included thrombo-
cytopenia (4.7%), decreased leukocyte count
(3.5%), and an increase in blood pressure
(1.2%), none of which led to discontinuation of
therapy.
Quinupristin/dalfopristin (7.5 mg/kg every
8 h) and linezolid (600 mg every 12 h) were
compared recently in terms of safety and effi-
cacy in the treatment of VRE infections in a
prospective randomized study of 40 cancer pa-
tients [71]. Linezolid and quinupristin/dalfo-
pristin had comparable clinical responses (58%
and 43%, respectively, p  0.6). Myalgias or
arthralgias occurred at a frequency of 33% in
patients who received quinupristin/dalfo-
pristin, but were not observed in the linezolid
group (p  0.03). In contrast, drug-related
thrombocytopenia occurred in 11% of patients
who received linezolid, but was not observed
in the quinupristin/dalfopristin group (p 
0.2). In cancer patients, quinupristin/dalfo-
pristin treatment is associated with a relatively
high frequency of myalgias/arthralgias; how-
ever, profound thrombocytopenia might limit
the choice of linezolid in a subpopulation of
cancer patients.
Linezolid resistance has been reported in a
small number of strains of E. faecium, which ap-
pears to be secondary to a base-pair mutation
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in the genome encoding for the bacterial 23S ri-
bosomal binding site [68]. These cases have sev-
eral features in common, including prolonged
duration of antimicrobial therapy, inadequate
source control, or non-removal of infected de-
vices. Several investigational agents are cur-
rently in phase 2 or 3 trials for VRE infection.
Tigecycline demonstrates potent in vitro activ-
ity against enterococci (MIC90 0.12 mg/L), re-
gardless of vancomycin susceptibility [72].
FUTURE STUDIES
An urgent need exists for more agents to
combat multi-drug-resistant, gram-positive
pathogens such as MRSA. The glycopeptide
oritavancin (LY333328) is in phase 3 clinical 
trials [73], whereas tigecycline has just been ap-
proved by the FDA. These agents, which re-
quire parenteral administration, exhibit sub-
stantial in vitro activity against a variety of
gram-positive aerobes and anaerobes, includ-
ing the multi-drug-resistant organisms de-
scribed above. If controlled clinical trial data
verify these agents’ efficacy and tolerability,
both drugs should become welcome additions
to the armamentarium for the treatment of re-
sistant, gram-positive pathogens.
New injectable cephalosporins with potent
activity against MRSA and gram-negative 
bacteria, are also being investigated actively
[74]. The new synthetic cephalosporin LB11058
has good affinity for staphylococcal penicillin-
binding protein 2a (PBP2a). At appropriate
doses, LB11058 was effective both in vitro and
in vivo in a rat aortic MRSA endocarditis model
[75]. This finding supports the development of
this agent for the treatment of MRSA infections.
Telavancin (TD-6424) is a novel lipogly-
copeptide that produces rapid, concentration-
dependent killing of clinically relevant gram-
positive organisms in vitro, including MRSA
and VRE. In vitro studies against specific MRSA
isolates documented that telavancin was 4- to
30-fold more potent than vancomycin and line-
zolid [76]. The findings of these studies collec-
tively suggest that once-daily dosing of tela-
vancin may provide an effective approach for
the treatment of clinically relevant infections
with resistant gram-positive organisms.
The development of parenteral carbapenems
with activity against MRSA is ongoing [77]. The
novel parenteral carbapenem ME1036 displays
broad activity against aerobic gram-positive
and gram-negative bacteria. Unlike other mar-
keted beta-lactam antibiotics, ME1036 has ex-
cellent activity against multiple-drug-resistant,
gram-positive bacteria such as MRSA. High
affinity for PBP2a accounts for the activity of
ME1036 against MRSA, for which the MIC50
was approximately 300-fold lower than that of
imipenem-cilastatin [78]. Thus, new carbapen-
ems may be promising candidates to treat
nosocomial bacterial infections caused by
gram-positive and gram-negative bacteria, es-
pecially multi-drug-resistant gram-positive
cocci.
Biofilm-associated infections are common,
including ventilator-associated pneumonia
and CR-BSI, and specific antibiotics targeted
against such device-related infections are be-
ing developed. A recent study documented
that ranbezolid inhibited biofilm formation 
to a greater extent than vancomycin, quin-
upristin-dalfopristin, and linezolid, and
therefore may prove useful in the prevention
and treatment of device-related infections
caused by staphylococci [79]. It is only
through the continued development of novel
antimicrobial agents that new treatment
strategies will emerge for multi-drug-resis-
tant, gram-positive infections.
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